Hepatic injury to the newborn liver due to drugs

Current Pharmaceutical Design

Volumn 18, Issue 21, 2012, Pages 3050-3060

  van Eyken, Peter ^a   Nemolato, Sonia ^b   Faa, Gavino ^b   Ambu, Rossano ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Drugs; Hepatitis; Hepatotoxicity; Liver

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; ERYTHROMYCIN; INDOMETACIN; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; VALPROIC ACID;

ACUTE HEPATITIS; BIRTH WEIGHT; DRUG BIOAVAILABILITY; DRUG DETOXIFICATION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG TRANSFORMATION; GASTROINTESTINAL MOTILITY DISORDER; GESTATIONAL AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION SENSITIVITY; KIDNEY FUNCTION; LIVER BIOPSY; LIVER CELL; LIVER FUNCTION; LIVER TOXICITY; LUNG DYSPLASIA; NEWBORN DISEASE; NEWBORN INFECTION; PATENT DUCTUS ARTERIOSUS; PRENATAL GROWTH; PRIORITY JOURNAL; REVIEW;

EID: 84862589711     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811209023050     Document Type: Review

References (181)

1. Dani C, Biadaioli R, Bertini G, Martelli E, Rubaltelli FF. Probiotics feeling in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. A prospective study. Biol Neonate 2002; 82: 103-8.
2. Manzoni P, Mostert M, Leonessa ML, et al. Oral sipplementation with Lactobacillus casei subspecies rhamnosus prevents enteric colonization by Candida species in preterm neonates: a randomized study. Clin Infect Dis 2006; 42: 1735-42.
3. Chirico G, Barbieri F, Chirico C. Antibiotics for the newborn. J Matern Fetal Neonatal Med 2009; 22 Suppl 3: 46-9.
4. Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Empirical use of ampicillin and cefotaxime, compared with ampicillin and gentamicin, for neonates at risk for sepsis is associated with an increased risk of neonatal death. Pediatrics 2006; 117: 67-74.
5. Meloni A, Melis M, Alba E, et al. Medical therapy in the management of preterm birth. J Matern Fetal Neonatal Med 2009; 22: 72-6.
6. Guimaraes H, Rocha G, Tomé T, Anatolitou F, Sarafidis K, Fanos V. Non-steroid anti-inflammatory drugs in the treatment of patent ductus arteriosus in European newborns. J Matern Fetal Neonatal Med 2009; 22: 77-80.
7. Kearns GL. Pharmacogenetics and development: are infants and children at increased risk for adverse outcomes? Curr Opin Pediatr 1995; 7: 220-33.
8. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology-Drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349: 1157-67.
9. Stewart CF, Hampton EM. Effect of maturation on drug disposition in pediatric patients. Clin Pharm 1987; 6: 548-64.
10. Morselli PL, Franco-Morselli R, Bossi L. Clinical pharmacokinetics in newborns and infants: age-related differences and therapeutic implications. Clin Pharmacokinet 1980; 5: 485-527.
11. Anderson GD. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia 2002; 43 (Suppl 3): 53-9.
12. De Gregori S, De Gregori M, Ranzani GN, Borghesi A, Regazzi M, Stronati M. Drug transporters and renal drug disposition in the newborn. J Maternal-Fetal Neonatal Med 2009; 22 (Suppl 3): 31-7.
13. Pineiro-Carrero VM, Pineiro EO. Liver. Pediatrics 2004; 113: 1097-106.
14. Buratti S, Lavine JE. Drugs and the liver: advances in metabolism, toxicity, and therapeutics. Curr Opin Pediatr 2002; 14: 601-7.
15. Treluyer JM, Rey E, Sonnier M, et al. Evidence of impaired cisapride metabolism in neonates. Br J Clin Pharmacol 2001; 52: 419-25.
16. Franconi F, Brunelleschi S, Steardo L, Cuomo V. Gender differences in drug responses. Pharmacol Res 2007; 55: 81-95.
17. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ. Adverse drug reactions as cause of admission to hospital. Brit Med J 2004; 329: 15-9.
18. Khurana S, Jaiswal AK, Mukhopadhyay A. Hepatocyte nuclear factor-4 induces transdifferentiation of hematopoietic cells into hepatocytes. J Biol Chem 2010; 285: 4725-31.
19. Faa G, Liguori C, Columbano A, Diaz G. Uneven copper distribution in the newborn liver. Hepatology 1987; 7: 838-42.
20. Faa G, Sciot R, Farci AM, et al. Iron concentration and distribution in the newborn liver. Liver 1994; 14: 193-9.
21. Coni P, Ravarino A, Farci AM, et al. Zinc content and distribution in the newborn liver. J Pediatr Gastroenterol Nutr. 1996;23: 125-9.
22. Zong Y, Panikkar A, Xu J, et al. Notch signaling controls liver development by regulating biliary differentiation. Development 2009; 136: 1727-39.
23. Gatmaitan Z, Varticovski L, Ling L, Mikkelsen R, Sreffan AM, Arias IM. Studies on fenestral contraction in rat liver endothelial cells in culture. Am J Physiol 1996; 148: 127-41.
24. Kohji Otogawa, Kohji Kinoshita, Hideki Fujii, et al. Erythrophagocytosis by Liver Macrophages (Kupffer Cells) Promotes Oxidative Stress, Inflammation, and Fibrosis in a Rabbit Model of Steatohepatitis. Am J Pathol 2009; 170: 967-80.
25. Sato M, Suzuki S, Senoo H. Hepatic stellate cells: unique characteristics in cell biology and phenotype. Cell Struct Funct 2003; 28: 105-12.
26. Kisseleva T, Brenner DA. Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. J Gastroenterol Hepatol 2007; 22 (Suppl 1): S73-8.
27. Jungermann K, Kietzmann T. Oxygen: Modulator of metabolic zonation and disease of the liver. Hepatology 2000; 31: 255-60.
28. Oinonen T, Lindros KO. Zonation of hepatic cytochrome P-450 expresion and regulation. Biochem J 1998; 329: 17-35.
29. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999; 37: 485-505.
30. Blake MJ, Castro L, Leeder JS, Kearns GL. Ontogeny of drug metabolizing enzymes in the neonate. Semin Fetal Neonatal Med 2005; 10: 123-38.
31. Leeder JS. Developmental and pediatric pharmacogenomics. Pharmacogenomics 2003; 4: 331-41.
32. Strolin Benedetti M, Baltes EL. Drug metabolism and disposition in children. Fundam Clin Pharmacol 2003; 17: 281-99.
33. Strolin Benedetti M, Whomsley R, Baltes EL. Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adultu populations. Expert Opin Drug Metab Toxicol 2005; 1: 447-71.
34. Hines RN. The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 2008; 118: 250-67.
35. Bjorkman S. Prediction of cytochrome P450-mediated hepatic drug clarance in neonates, infants and children: how accurate are available scaling methods? Clin Pharmacokinet 2006; 45: 1-11.
36. Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 2006; 45: 1077-97.
37. Anderson GD. Developmental pharmacokinetics. Semin Pediatr Neurol 2010; 17: 208-13.
38. Stahlberg MR, Hietanen E, Maki M. Mucosal biotransformation rates in the small intestine of children. Gut 1988; 29: 1058-63.
39. Yanowitz TD, Yao AC, Pettigrew KD, Werner JC, Oh W, Stonestreet BS. Postnatal hemodynamic changes in very-low-birthweight infants. J Appl Physiol 1999; 87: 370-80.
40. Greenblatt DJ, Koch-Weser J. Intramuscular injection of drugs. N Engl J Med 1976; 295: 542-6.
41. Wood AJJ, Drug therapy. N Engl J Med 2003; 349: 1157-67.
42. Brion LP, Fleischman AR, Schwartz GJ. Gentamicin interval in newborn infants as determined by renal function and postconceptional age. Pediatr Nephrol 1991; 5: 675-9.
43. Ehrnebo M, Agurell S, Jalling B, Boreus LO. Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults. Eur J Clin Pharmacol 1971; 3: 189-93.
44. Besunder JB, Reed MD, Blumer JL. Principles of drug predisposition in the neonate. A critical evaluation of the pharmacokineticpharmacodynamic interface (Part. I). Clin Pharmacokinet 1988; 14: 189-216.
45. Yan J, Cai Z. Molecular evolution and functional divergence of cytochrome P450 3 (CYP3) family in actinopterygii (Ray-finned fish). PlosOne 2010; 5: e14276.
46. Wrighton SA, Stevens JC. The human hepatic cytochrome P450 involved in drug metabolism. Crit Rev Toxicol 1992; 22: 1-21.
47. Ma JD, Nafziger AN, Bertino JS Jr. Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers. J Clin Pharmacol 2004; 44: 447-56.
48. Hines RN, McCarver DG. The ontogeny of human drugmetabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 2002; 300: 355-60.
49. de Wildt SN. Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children. Expert Opin Drug Metab Toxicol 2011; 7(8): 935-48.
50. Cummings AJ, Withelaw AG. A study of conjugation and drug elimination in the human neonate. Br J Clin Pharmacol 1981; 12: 511-5.
51. Gow PJ, Ghabrial H, Smallwood RA, Morgan DJ, Ching MS. Neonatal hepatic drug elimination. Pharmacol Toxicol 2001; 88: 3-15.
52. Suzuki Y, Cox S, Hayes J, et al. Valproic acid dosages necessary to maintain therapeutic concentrations in children. Ther Drug Monit 1991; 13: 314-7.
53. Cloyd JC, Kriel RL, Fischer JH, et al. Pharmacokinetics of valproic acid in children: multiple antiepileptic drug therapy. Neurology 1983; 33: 185-91.
54. Izzo AA, Arnst E. Interactions betwen herbal medicines and prescribed drugs: a systematic review. Drugs 2001; 61: 2163-75.
55. De Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Glucuronidation in humans: pharmacogenetic and developmental aspects. Clin Pharmacokinet 1999; 36: 439-52.
56. Riffel AK, Schuenemann E, Vyhlidal CA. Regulation of the CYP3A4 and CYP3A7 promoters by members of the nuclear factor I transcription factor family. Mol Pharmacol 2009; 76: 1104-14.
57. de Wildt SN, Kearns GL, Murry DJ, Koren G, van den Anker JN. Ontogeny of midazolam glucuronidation in preterm infants. Eur J Pharmacol 2010; 66: 165-70.
58. Elapavaluru S, Kellum JA. Why do patients die of acute kidney injury? Acta Clin Belg Suppl 2007; 2: 326-31.
59. Paladino JD, Hotchkiss JR, Rabb H. Acute kidney injury and lung disfunction: a paradigm for remore organ effects of kidney disease? Microvasc Res 2009; 77: 8-12.
60. Grigoryev DN, Liu M, Hassoun HT, et al. The local and systemic inflammatory transcriptome after acute kidney injury. J Am Soc Nephrol 2008; 19: 547-58.
61. Park SW, Chen SW, Kim M, et al. Cytokines induce small intestine and liver injury after ischemia or nephrectomy. Lab Invest 2011; 91: 63-84.
62. Nguyen CQ, Yin H, Lee BH, Chiorini JA, Peck AB. IL17: potential therapeutic target in Sjogren syndrome using adenovirus-mediated gene transfer. Lab Invest 2011; 91: 54-62.
63. Wang BY, Li QX, Li J, Xie XF, Ao Y, Ai YX. Hepatotoxicity and gene expression down regulation of CYP isoenzymes caused by renal ischemia/reperfusion in the rat. Exp Toxicol Pathol 2009; 61: 169-76.
64. Zager RA. Subclinical gentamycin nephrotoxicity: a potential risk factor for exaggerated endotoxin-driven TNF-production. Am J Physiol Renal Physiol 2007; 293: F1373-80.
65. Nagai J, Tanaka H, Nakanishi N, Murakami T, Takano M. Role of megalin in renal handling of aminoglycosides. Am J Physiol Renal Physiol 2001; 281: F337-44.
66. Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010; 52: 730-42.
67. Suzuki A, Andrade RJ, Bjornsson E, et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf 2010; 33: 503-22.
68. Bjornsson ES. Drug-induced liver injury. Laeknabladid 2010; 96: 175-82.
69. Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010; 51: 2117-26.
70. Liss G, Lewis JH. Drug-induced liver injury:what was new in 2008? Expert Opin Drug Metab Toxicol 2009; 5: 843-60.
71. Assis DN, Navarro VJ. Human drug hepatotoxicity: a contemporary clinical prospective. Expert Opin Drug Metab Toxicol 2009; 5: 463-73.
72. Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009; 32: 55-68.
73. Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008; 47: 2003-9.
74. Bjornsson E. The natural history of drug-induced liver injury. Semin Liver Dis 2009; 29: 357-63.
75. Roth RA, Ganey PE. Intrinsic versus idiosyncratic drug-induced hepatotoxicity: two villains or one? J Pharmacol Exp Ther 2010; 332: 692-7.
76. Grunhage F, Fischer HP, Sauerbruch T, Reichel C. Drug-and toxin-induced hepatotoxicity. Z Gastroenterol 2003; 41: 565-78.
77. Bohan A, Boyer JL. Mechanisms of hepatotoxicity transport of drugs: implications for cholestatic drug reaction. Semin Liver Dis 2002; 22: 123-36.
78. Karpen SJ, Suchy FJ. In: Suchy FJ, Sokol RJ, Balistreri WF, Eds. Liver Disease in children, Philadelphia: Lippincot Williams & Wilkins Co. 2001: pp 3-21.
79. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349: 474-85.
80. Faa G, Ambu R, Congiu T, et al. Early ultrastructural changes during thioacetamide-induced apoptosis in rat liver. J Submicrosc Cytol Pathol 1992; 24: 417-24.
81. Reed DJ. In: Plaa GL, Hewitt WR, Eds. Toxicology of the Liver. Washington: Taylor and Francis Co. 1998; pp. 221-57.
82. Lewis JH, Kleiner DE. In: Burt AD, Portmann BC, Ferrell LD Eds. MacSween's Pathology of the Liver. Churchill Livingstone Elseviere. 2007; pp. 649-759.
83. Mitchell JR, Jollow DJ, Potter WZ. Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther 1973; 187: 185-94.
84. Zimmerman HJ. Effects of aspirin and acetaminophen on the liver. Arch Intern Med 1981; 141: 333-42.
85. Starko KM, Mullick FG. Hepatic and cerebral pathology findings in children with fatal salicylate intoxication: further evidence for a causal relation between salicylate and Rey's syndrome. Lancet 1983; i:326-29.
86. Schenker S, Breen KJ, Heimberg M. In: Gerok W, Sickinger K Eds. Pathogenesis of tetracycline induced fatty liver. Stuttgart: FK Schattauer-Verlag Co. 1972; pp. 269-80.
87. Eadie MJ, Hooper WD, Dickinson RG. Valproate-associated hepatotoxicity and its biochemical mechanisms. Med Toxicol Adverse Drug Exp 1988; 3: 85-105.
88. Kleiner DE. The pathology of drug-induced liver injury. Semin Liver Dis 2009; 29: 364-72.
89. Furst SM, Gandolfi AJ. In: Plaa GL, Hewitt WR, Eds. Toxicology of the Liver. Washington: Taylor and Francis Co. 1998; pp. 259-96.
90. Khandelwal N, James LP, Sanders C, Larson AM, Lee WM, and the Acute Liver Failure Study Group. Unrecognized acetaminophen toxicity of indeterminate acute liver failure. Hepatology 2011; 53: 567-76.
91. Murray KF, Hadzic N, Wirth S, Bassett M, Kelly D. Drug-related hepatotoxicity and acute liver failure. J Pediatr Gastroenterol Nutr 2008; 47: 395-405.
92. Marzullo R. An update on N-acetylcysteine treatment for acute acetaminophen toxicity in children. Curr Opin Pediatr 2005; 17: 239-45.
93. Miller RP, Roberts RJ, Fischer LJ. Acetaminophen elimination kinetics in neonates, children, and adults. Clin Pharmacol Ther 1976; 19: 284-94.
94. Roberts EA. In: Suchy FJ, Sokol RJ, Balistreri WF, Eds. Liver Disease in Children. Philadelphia: Lippincot Williams & Wilkins Co. 2001; pp. 463-91.
95. Dart RC, Bailey E. Does therapeutic use of acetaminophen cause acute liver failure? Pharmacotherapy 2007; 27: 1219-30.
96. Walls L, Baker CF, Sarkar S. Acetaminophen-induced hepatic failure with encephalopathy in a newborn. J Perinatol 2007; 27: 133-5.
97. Ebenezer K, Agarwal I, Fleming D. Acute hepatic failure in an infant caused by acetaminophen (paracetamol) toxicity. Ann Trop Paediatr 2008; 28: 301-3.
98. Squires RH Jr, Shneider BL, Bucuvalas J et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 2006; 148: 652-8.
99. Hu J, Yan D, Gao J, Xu C, et al. rhIL-1Ra reduces hepatocellular apoptosis in mice with acetaminophen-induced acute liver failure. Lab Invest 2010; 90: 1737-46.
100. Hu B, Colletti LM. CXC receptor-2 knockout genotype increases X-linked inhibition of apoptosis protein and protects mice from acetaminophen hepatotoxicity. Hepatology 2010; 52: 691-702.
101. Jaeschke H, Williams CD, Farhood A. No evidence for caspasedependent apoptosis in acetaminophen hepatotoxicity. Hepatology 2011; 53: 718-9 (letter).
102. Ishak KG. Granulomas of the liver. Adv Pathol Lab Med 1995; 8: 247-361.
103. Holt MP, Cheng L, Ju C. Identification and characterization of infiltrating mecrophages in acetaminophen-induced liver injury. J Leukoc Biol 2008; 84: 1410-21.
104. Ishida Y, Kondo T, Kimura A, Tsuneyama K, Takayasu T, Mukaida N. Opposite roles of neutrophils and macrophages in the pathogenesis of acetaminophen-induced acute liver injury. Eur J Immunol 2006; 36: 1028-38.
105. Ishida Y, Kondo T, Ohshima T, Fujiwara H, Iwakura Y, Mukaida N. A pivotal involvement of IFN-gamma in the pathogenesis of acetaminophen-induced acute liver injury. FASEB J 2002; 16: 1227-36.
106. Ballard HO, Shook LA, Bernard P, et al. Use of azithromycin for the prevention of bronchopulmonary dysplasia in preterm infants: a randomized, double blind, placebo controlled trial. Pediatr Pulmonol 2011; 46: 111-8.
107. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34.
108. Ghabril M, Chalasani N, Bjornsson E. Drug-induced liver injury: a clinical update. Curr Opin Gastroenterol 2010; 26: 222-6.
109. Robles M, Toscano E, Cotta J, Lucena MI, Andrade RJ. Antibioticinduced liver toxicity: mechanisms, clinical features and causality assessment. Curr Drug Saf 2010; 5: 212-22.
110. Cotten CM, Taylor S, Stoll B, et al. NICHD Neonatal Research Network. Prolonged duration of empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics 2009; 123: 58-66
111. Lewis JH, Zimmerman HJ. Drug-and chemical-induced cholestasis. Clin Liver Dis 1999; 3: 433-64.
112. Cundiff J, Joe S. Amoxicillin-clavulanic acid-induced hepatitis. Am J Otolaryngol 2007; 28: 28-30.
113. Reuben A. Needles in haystacks. Am J Gastroenterol 2007; 102: 2444-6.
114. Gresser U. Amoxicillin-clavulanic acid therapy may be associated with severe side effects-review of the literature. Eur J Med Res 2001; 20: 139-49.
115. Jordan T, Gonzàles M, Casado M, et al. Amoxicillin-clavulanic acid induced hepatotoxicity with progression to cirrhosis. Gastroenterol Hepatol 2002; 25: 240-3.
116. Hartleb M, Biernat L, Kochel A. Drug-induced liver damage-a three-year study of patients from one gastroenterological department. Med Sci Monit 2002; 8: CR292-6.
117. Zaidi SA. Hepatitis associated with amoxicillin-clavulanic acid and/or ciprofloxacin. Am J Med Sci 2003; 325: 31-3.
118. Robles M, Andrade RJ. Hepatotoxicity by antibiotics: update in 2008. Rev Esp Quimioter 2008; 21: 224-33.
119. Hautekeete ML. Hepatotoxicity and antibiotics. Acta Gastroenterol Belg 1995; 58: 290-6.
120. Breuskin F, Horsmans Y, Rahier J, Lambert M. Recurrent immunoallergic hepatitis related to amoxicillin-clavulanic acid. Acta Clin Belg 2001; 56: 255-7.
121. Cotten CM, McDonald S, Stoll B, Goldberg RN, Poole K, Benjamin DK Jr. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics 2006; 118: 717-22.
122. Zafrani ES, Ishak KG, Rudzki C. Cholestatic and hepatocellular injury associated with erythromycin esters: report of nine cases. Am J Dig Dis 1979; 24: 385-96.
123. Chandrupatla S, Demetris AJ, Rabinowitz M. Azythromycininduced intrahepatic cholestasis. Dig Dis Sci 2002; 47: 2186-8.
124. Trollfors B, Norrby R, Bergmark J, Linderholm H. Comparative toxicity of gentamicin and cefotetan. Scand J Infect Dis 1986; 18: 139-46.
125. Lv H, Liu L, Zhang Y, Lu J, Chen X. Ingenuity pathway analysis of urine metabonomics phenotypes toxicity of gentamicin in multiple organs. Mol Biosyst 2010; 6: 2056-67.
126. Crann SA, Huang MY, McLaren JD, Schacht J. Formation of a toxic metabolite from gentamicin by a hepatic cytosolic fraction. Biochem Pharmacol 1992; 43: 1835-
127. Szefler SJ, Wynn RJ, Clarke DF, Buckwald S, Shen D, Schentag JJ. Relationship of gentamicin serum concentrations to gestational age in preterm and term neonates. J Pediatr 1980, 97, 312-5.
128. Weiss CF, Glazko AJ, Weston JK. Chloramphenicol in the newborn infant: a physiologic explanation of its toxicity when given in excessive doses. N Engl J Med 1960; 262: 787-94.
129. Young WS, Lietman PS. Chloramphenicol glucuronyl transferase: assay, ontogeny and inducibility. J Pharmacol Exp Ther 1978; 204: 203-11.
130. Hart FD, Boardman PL. Ibufenac (4-isobutylphenyl acetic acid). Ann Rheum Dis 1965; 24: 61-5.
131. Aranda JV, Beharry KD, Valencia GB. Nonsteroidal antiinflammatory drugs (NSAIDs) in the newborn-which ones? J Maternal-Fetal Neonatal Med 2009; 22: 21-2.
132. Aranda JV, Thomas R. Systematic review: intravenous Ibuprofen in preterm newborns. Semin Perinatol 2006; 30: 114-20.
133. Van Overmeire B, Smets K, Lecoutere D, et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med 2000; 343: 674-8
134. Heymann MA, Rudolph AM, Silverman NH. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med 1976; 295: 530-3.
135. Antonucci R, Cuzzolin R, Arceri A, Dessì A, Fanos V. Changes in urinary PGE2 after ibuprofen treatment in preterm infants with patent ductus arteriosus. Eur J Clin Pharmacol 2009; 65: 223-30.
136. Itabashi K, Ohno T, Nishida H. Indomethacin responsiveness of patent ductus arteriosus and renal abnormalities in preterm infants treated with indomethacin. J Pediatr 2003; 143: 203-7.
137. Lago P, Bettiol T, Salvadori S, et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomized controlled trial. Eur J Pediatr 2002; 161: 202-7.
138. Patel J, Roberts I, Azzopardi D, Hamilton P, Edwards A. Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. Pediatr Res 2000; 47: 36-42.
139. Pezzati M, Vangi V, Biagiotti R, Bertini G, Ciaciulli D, Rubaltelli F. Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J Pediatr 1999; 135: 733-8.
140. Grosfeld J, Chaet M, Molinari F, et al. Increased risk of necrotizing enterocolitis in premature infants with patent ductus arteriosus treated with indomethacin. Ann Surg 1996; 224: 350-7.
141. Guthrie S, Gordon P, Thomas V, Thorp J, Peabody J, Clark R. Necrotizing enterocolitis among neonates in the Unites States. J Perinatol 2003; 23: 278-85.
142. Fenech FF, Bannister WH, Grech JL. Hepatitis with biliverdinemia in association with indomethacin therapy. Br Med J 1967; 15: 155-6.
143. Kelsey WM, Scharyj M. Fatal hepatitis probably due to indomethacin. JAMA 1967; 199: 586-7.
144. Balduck N, Otten J, Verbruggen L, Bougatef A, Ramet J, Piepsz A. Sudden death of a child with juvenile chronic arthritis, probably due to indomethacin. Eur J Pediatr 1987; 146: 620.
145. Thomas R, Parker G, Van Overmeire B, Aranda J. A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus. Eur J Pediatr 2005; 164: 135-40.
146. Ohlsson A, Walia R, Shah S. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2008; 1: CD003481.
147. Mercanti I, Boubred F, Simeoni U. Therapeutic closure of the ductus arteriosus: benefits and limitations. J Matern Fetal Neonatal Med 2009; 22(S3): 14-20.
148. Naulaers G, Delanghe G, Allegaert K, et al. Ibuprofen and cerebral oxygenation and circulation. Arch Dis Child Fetal Neonatal Ed 2005; 90: F75-F76.
149. Gournay V, Savagner C, Thiriez G, Kuster A, Roze J. Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants. Lancet 2002; 359: 1486-8.
150. Laurent S, Rahier J, Geubel AP, Lerut J, Horsmans Y. Subfulminant hepatitis requiring liver transplatation following ibuprofen overdose. Liver 2000; 20: 93-4.
151. Alam I, Ferrell LD, Bass NM. Vanishing bile duct syndrome temporally associated with ibuprofen use. Am J Gastroenterol 1996; 91: 1626-30.
152. Srivastava M, Perez-Ataide A, Jonas MM. Drug-associated acute onset vanishing bile duct and Stevens-Johnson syndrome in a child. Gastroenterology 1998; 115: 743-6.
153. Zucker P, Daum F, Cohen MI. Aspirin hepatitis. Am J Dis Child 1975; 129: 1433-4
154. Prescott LF. Hepatotoxicity of mild analgesics. Br J Clin Pharmacol 1980; 10 (Suppl 2): 373S-9.
155. Tanret I, Duh D. The Reye Syndrome. J Pharm Bel 2011; 1: 13-15.
156. Pugliese A, Beltramo T, Torre D. Reye's and Reye's-like syndromes. Cell Biochem Funct 2008; 26: 741-6.
157. White JM. Reye's syndrome and salicylates (letter). JAMA 1987; 258: 3117.
158. MacDonald S. Aspirin use to be banned in under 16 year olds. Br Med J 2002; 375: 988.
159. Cohen KA, Hopkins J, Ingraham RH. Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase. J Biol Chem 1991; 266: 14670-4.
160. Johnson S, Chan J, Bennett CL. Hepatotoxicity after prophylaxis with a nevirapine-containing antiretroviral regimen. Ann Intern Med 2002; 137: 146-7.
161. Stern JO, Robinson PA, Love J. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003; 34: S21-S33.
162. McKoy JM, Bennett CL, Scheetz MH, et al. Hepatotoxicity associated with long-versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the research on adverse drug events and reports (RADAR) project. Drug Saf 2009; 32: 147-58.
163. Dickinson RG, Hooper WD, Dunstan PR, Eadie MG. Urinary excretion of valproate and some metabolites in chronically treated patients. Ther Drug Monit 1989; 11: 127-33.
164. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987; 37: 379-85.
165. Bryant AE, Dreifuss FE. Valproic acid hepatic fatalities, III: U S experience since 1986. Neurology 1996; 46: 465-9.
166. Scheffner D, Konig S, Rauterberg-Ruland I, Kochen W, Hofmann WJ, Unkelbach S. Fatal liver failure in 16 children with valproate therapy. Epilepsia 1988; 29: 530-42.
167. Krahenbuhl S, Brandner S, Kleinle S, Liechti S, Straumann D. Mitochondrial diseases repesent a risk factor for valproate-induced fulminant liver failure. Liver 2000; 20: 346-8.
168. Appleton RE, Farrell K, Applegarth DA, Dimmick JE, Wong LT, Davidson AG. The high incidence of valproate hepatotoxicity in infants may relate to familial metabolic defects. Can J Neurol Sci 1990; 17: 145-8.
169. Fromenty B, Pessayre D. Inhibition of mitochondrial betaoxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995; 67: 101-54.
170. Kesterson JW, Granneman GR, Machinist JM. The hepatotoxicity of valproic acid and its metabolites in rats, I: toxicologic, biochemical and histopathologic studies. Hepatology 1984; 4: 1143-52.
171. Shen DD, Pollack GM, Cohen ME. Effect of age on the serum metabolite pattern of valproic acid in epileptic children. Epilepsia 1984; 5: 674 (abstract).
172. Levy RH, Rettenmeier AW, Anderson GD, et al. Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate: a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther 1990; 48: 225-35.
173. Schlienger RG, Knowles SR, Shear NH. Lamotrigine-associated anticonvulsant hypersensitivity syndrome. Neurology 1998; 51: 1172-5.
174. Anderson GD, Yau MK, Gidal BE, et al. Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther 1996; 60: 145-56.
175. Maggs JL, Nasibitt DJ, Tattey JNA, Pirmohamed M, Park BK. Metabolism of lamotrigine to a reactive arene oxide intermediate. Chem Res Toxicol 2000; 13: 1075-81.
176. Mockli G, Crowley M, Stern R, Warnock ML. Massive hepatic necrosis after administration of phenobarbital. Am J Gastroenterol 1989; 84: 820-2.
177. Andreu V, Mas A, Bruguera M, et al. Ectasy: a common cause of severe acute hepatotoxicity. J Hepatol 1998; 29: 394-7.
178. Dykhuizen RS, Brunt PW, Atkinson P, Simpson JG, Smith CC. Ectasy-induced hepatitis mimiking viral hepatitis. Gut 1995; 36: 939-41.
179. Nunez O, Banares R, Barrio J, et al. Variability of the clinical expression of ectasy-induced hepatotoxicity. Gastroenterol Hepatol 2002; 25: 497-500.
180. Lange-Brock N, Berg T, Muller AR, et al. Acute liver failure following the use of ectasy (MDMA). Z Gastroenterol 2002; 40: 581-6.
181. Dahshan A. Prenatal exposure to metamphetamine presenting as neonatal cholestasis. J Clin Gastroenterol 2009; 43: 88-90.